Overview

LyoLife™ freeze-dries stem/progenitor cells from peripheral blood, umbilical cord blood, bone marrow, and adipose tissuefor storage at room temperature and rehydration for use in cell therapy. In the fields of cell therapy and regenerative medicine – the processes of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects – LyoLife research has demonstrated DNA integrity and cell viability after freeze-drying and rehydration, and has shown that hematopoietic stem cells retain their ability to differentiate into to a variety of specialized blood cells.

Research

Sheep peripheral blood lymphocytes & granulosa cells
Freeze-dried somatic cells direct embryonic development after nuclear transfer
P. Loi, K. Matsukawa, G. Ptak, M. Clinton, J. Fulka Jr., Y. Natan, A. Arav

Human umbilical cord blood stem cells
Freeze-drying of mononuclear cells derived from umbilical cord blood follow by colony formation
Y. Natan, A. Nagler, A. Arav

Human neuro-like stem cells
Confidential project led by a leading PharmaCo developing a cell therapy product for the treatment of Alzheimer disease
A. Arav, Y. Natan

Freeze-dried human mesenchymal stem cells
Confidential project led by global biotechnology company developing a treatment for anal fissure using mesenchymal stem cells
A. Arav, Y. Natan

Human bone marrow tissue
Unpublished research exploring the potential for freeze-drying human bone marrow tissue
A. Arav, Y. Natan

Market

Market size & growth

The global regenerative medicine market is forecast to reach $50 billion by 2025, growing by 13% year-on-year, within which the cell therapy segment will continue to dominate vs. gene therapy and tissue engineering

Key trends & information

The major factors driving the Regenerative Medicine market include:

  • Overall ageing population trends due to falling fertility rates and increased life expectancy, and growing healthcare expenditure
  • Increasing prevalence of chronic diseases, degenerative diseases, and trauma emergencies, and shortage of organs for transplantation
  • Technological advancements in tissue and organ regeneration, and nanotechnology use in wound care, drug delivery and immunomodulation
  • Growth in funding, including governmental programs in Canada, Japan, and the US to establish centers of excellence, manufacturing infrastructure and research networks

Shifting the focus from treatment to healing, regenerative medicine signifies a major revolution for patients, healthcare systems, and bio-pharma players:

  • The healthcare ecosystem will have to adapt as regenerative medicine requires special patient settings for application and new forms of reimbursement
  • Big Pharma will need to catch-up, with the regenerative medicine field currently led by bio-tech and med-tech players, along with academic research centers
  • A growing range of private-public collaborations and more liberal laws surrounding stem cell technologies will place certain countries at the forefront of regenerative medicine

Source: Global Regenerative Medicines Market – Analysis and Forecast (2017-2025), BIS Research